NCT04373031 2025-12-02
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Providence Health & Services
Phase 2 Active not recruiting
Providence Health & Services
University of Southern California
Brooklyn ImmunoTherapeutics, LLC
Brooklyn ImmunoTherapeutics, LLC